Current approaches in lipid-based nanocarriers for oral drug delivery

Drug Deliv Transl Res. 2021 Apr;11(2):471-497. doi: 10.1007/s13346-021-00908-7. Epub 2021 Feb 2.

Abstract

Lipid-based nanocarriers have gained much interest as carriers of drugs with poor oral bioavailability because of their remarkable advantages like low toxicity, affordable scale-up manufacture, strong biocompatibility or high drug loading efficiency. The potential of these nanocarriers lies in their ability to improve the gastrointestinal stability, solubility and permeability of their cargo drugs. However, achieving efficient oral drug delivery through lipid-based nanocarriers is a challenging task, since they encounter multiple physicochemical barriers along the gastrointestinal tract, e.g. the gastric acidic content, the intestinal mucus layer or the enzymatic degradation, that they must surmount to reach their target. These limitations may be turned into opportunities through a rational design of lipid-based nanocarriers. For that purpose, this review focuses on the main challenges of the oral route indicating the strategies undertaken for lipid-based nanocarriers in order to overcome them. Understanding their shortcomings and identifying their strengths will determine the future clinical success of lipid-based nanocarriers.

Keywords: Liposome; Nanocapsule; Nanoemulsion; Oral delivery; Self-emulsifying system; Solid-lipid nanoparticle.

Publication types

  • Research Support, Non-U.S. Gov't
  • Review

MeSH terms

  • Administration, Oral
  • Biological Availability
  • Drug Carriers*
  • Drug Delivery Systems
  • Lipids
  • Nanoparticles*

Substances

  • Drug Carriers
  • Lipids